- Home
- NG vs TGTX Comparison
NG vs TGTX Comparison
Compare NG & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NG | TGTX |
|---|---|---|
| Founded | 1984 | 1993 |
| Country | Canada | United States |
| Employees | 12 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.0B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | NG | TGTX |
|---|---|---|
| Price | $10.71 | $28.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $10.83 | ★ $50.67 |
| AVG Volume (30 Days) | ★ 5.3M | 1.6M |
| Earning Date | 03-31-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | N/A | ★ $531,898,000.00 |
| Revenue This Year | N/A | $90.46 |
| Revenue Next Year | N/A | $46.39 |
| P/E Ratio | ★ N/A | $10.27 |
| Revenue Growth | N/A | ★ 100.88 |
| 52 Week Low | $2.26 | $25.28 |
| 52 Week High | $12.09 | $46.48 |
Technical Indicators
Market Signals| Indicator | NG | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 43.62 |
| Support Level | $8.22 | $27.93 |
| Resistance Level | $11.92 | $30.00 |
| Average True Range (ATR) | 1.01 | 1.02 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 51.03 | 30.96 |
Price Performance
Historical ComparisonAbout NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other precious metals.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.